Cargando…
Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality
Statin use and its impact on long-term clinical outcomes in active cancer patients following acute myocardial infarction (MI) remains insufficiently elucidated. Of the 1011 consecutive acute MI patients treated invasively between 2012 and 2017, cancer was identified in 134 (13.3%) subjects. All pati...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330549/ https://www.ncbi.nlm.nih.gov/pubmed/35893743 http://dx.doi.org/10.3390/ph15080919 |
_version_ | 1784758188263866368 |
---|---|
author | Stepien, Konrad Nowak, Karol Kachnic, Natalia Horosin, Grzegorz Walczak, Piotr Karcinska, Aleksandra Schwarz, Tomasz Wojtas, Mariusz Zalewska, Magdalena Pastuszak, Maksymilian Wegrzyn, Bogdan Nessler, Jadwiga Zalewski, Jarosław |
author_facet | Stepien, Konrad Nowak, Karol Kachnic, Natalia Horosin, Grzegorz Walczak, Piotr Karcinska, Aleksandra Schwarz, Tomasz Wojtas, Mariusz Zalewska, Magdalena Pastuszak, Maksymilian Wegrzyn, Bogdan Nessler, Jadwiga Zalewski, Jarosław |
author_sort | Stepien, Konrad |
collection | PubMed |
description | Statin use and its impact on long-term clinical outcomes in active cancer patients following acute myocardial infarction (MI) remains insufficiently elucidated. Of the 1011 consecutive acute MI patients treated invasively between 2012 and 2017, cancer was identified in 134 (13.3%) subjects. All patients were observed within a median follow-up of 69.2 (37.8–79.9) months. On discharge, statins were prescribed less frequently in MI patients with cancer as compared to the non-cancer MI population (79.9% vs. 91.4%, p < 0.001). The most common statin in both groups was atorvastatin. The long-term mortality was higher in MI patients not treated vs. those treated with statins, both in non-cancer (29.5%/year vs. 6.7%/year, p < 0.001) and cancer groups (53.9%/year vs. 24.9%/year, p < 0.05), respectively. Patient’s age (hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.03–1.05, p < 0.001, per year), an active cancer (HR 2.42, 95% CI 1.89–3.11, p < 0.001), hemoglobin level (HR 1.14, 95% CI 1.09–1.20, p < 0.001, per 1 g/dL decrease), and no statin on discharge (HR 2.13, 95% CI 1.61–2.78, p < 0.001) independently increased long-term mortality. In MI patients, simultaneous diagnosis of an active cancer was associated with less frequently prescribed statins on discharge. Irrespective of cancer diagnosis, no statin use was found as an independent predictor of increased long-term mortality. |
format | Online Article Text |
id | pubmed-9330549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93305492022-07-29 Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality Stepien, Konrad Nowak, Karol Kachnic, Natalia Horosin, Grzegorz Walczak, Piotr Karcinska, Aleksandra Schwarz, Tomasz Wojtas, Mariusz Zalewska, Magdalena Pastuszak, Maksymilian Wegrzyn, Bogdan Nessler, Jadwiga Zalewski, Jarosław Pharmaceuticals (Basel) Article Statin use and its impact on long-term clinical outcomes in active cancer patients following acute myocardial infarction (MI) remains insufficiently elucidated. Of the 1011 consecutive acute MI patients treated invasively between 2012 and 2017, cancer was identified in 134 (13.3%) subjects. All patients were observed within a median follow-up of 69.2 (37.8–79.9) months. On discharge, statins were prescribed less frequently in MI patients with cancer as compared to the non-cancer MI population (79.9% vs. 91.4%, p < 0.001). The most common statin in both groups was atorvastatin. The long-term mortality was higher in MI patients not treated vs. those treated with statins, both in non-cancer (29.5%/year vs. 6.7%/year, p < 0.001) and cancer groups (53.9%/year vs. 24.9%/year, p < 0.05), respectively. Patient’s age (hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.03–1.05, p < 0.001, per year), an active cancer (HR 2.42, 95% CI 1.89–3.11, p < 0.001), hemoglobin level (HR 1.14, 95% CI 1.09–1.20, p < 0.001, per 1 g/dL decrease), and no statin on discharge (HR 2.13, 95% CI 1.61–2.78, p < 0.001) independently increased long-term mortality. In MI patients, simultaneous diagnosis of an active cancer was associated with less frequently prescribed statins on discharge. Irrespective of cancer diagnosis, no statin use was found as an independent predictor of increased long-term mortality. MDPI 2022-07-25 /pmc/articles/PMC9330549/ /pubmed/35893743 http://dx.doi.org/10.3390/ph15080919 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stepien, Konrad Nowak, Karol Kachnic, Natalia Horosin, Grzegorz Walczak, Piotr Karcinska, Aleksandra Schwarz, Tomasz Wojtas, Mariusz Zalewska, Magdalena Pastuszak, Maksymilian Wegrzyn, Bogdan Nessler, Jadwiga Zalewski, Jarosław Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality |
title | Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality |
title_full | Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality |
title_fullStr | Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality |
title_full_unstemmed | Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality |
title_short | Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality |
title_sort | statin use in cancer patients with acute myocardial infarction and its impact on long-term mortality |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330549/ https://www.ncbi.nlm.nih.gov/pubmed/35893743 http://dx.doi.org/10.3390/ph15080919 |
work_keys_str_mv | AT stepienkonrad statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT nowakkarol statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT kachnicnatalia statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT horosingrzegorz statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT walczakpiotr statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT karcinskaaleksandra statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT schwarztomasz statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT wojtasmariusz statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT zalewskamagdalena statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT pastuszakmaksymilian statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT wegrzynbogdan statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT nesslerjadwiga statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality AT zalewskijarosław statinuseincancerpatientswithacutemyocardialinfarctionanditsimpactonlongtermmortality |